Research Site

Granby, Quebec J2G 8Z9

1 studies enrolling now · 11 studies all time

What they study most

Acute Coronary Syndrome, Dyslipidemia, Elevated High-sensitivity C-Reactive Protein (hsCRP), Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD), Hypercholesterolemia, Hyperlipidemia, Hyperlipidemia and Mixed Dyslipidemia, Prostate Cancer, Type 2 Diabetes

Studies at this site

• Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS — Recruiting now
• Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk — Completed
• Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2 — Completed
• Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels — Completed
• Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS — Completed
• Open Label Study of Long Term Evaluation Against LDL-C Trial — Completed
• Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia — Completed
• Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia — Completed
• A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases — Completed
• JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events — Stopped early
• GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes — Completed